NEW YORK, Aug 6 - Synaptic Pharmaceutical of Paramus, NJ, said it planned to raise $41 million in two stages of private financing.

Under the terms of the deal, investment firm Warburg Pincus has agreed to purchase 2.2 million series B preferred shares representing 19.9 percent of the company’s stock for $9.4 million. Warburg Pincus has also agreed to purchase additional convertible shares valued at $31.6 million in a second tranche combining series B and C preferred stock.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Human Longevity alleges that Craig Venter stole trade secrets in a lawsuit filed against the J. Craig Venter Institute.

A new paper critiques the analysis and conclusions of the Atacama mummy genome sequencing study.

An Associated Press poll finds that most US adults say they'd want to know whether they carried a gene variant predisposing them to an incurable disease.

In PLOS this week: transcription levels linked to uracil mutations, transcriptomic analysis of medicinal leech, and more.